Skip to main content

Skyrizi Side Effects

Generic name: risankizumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 29, 2022.

Note: This document contains side effect information about risankizumab. Some of the dosage forms listed on this page may not apply to the brand name Skyrizi.

For the Consumer

Applies to risankizumab: parenteral injection

Side effects include:

Common adverse effects (≥1%): Upper respiratory infection, headache, fatigue, injection site reaction, tinea infection.

For Healthcare Professionals

Applies to risankizumab: intravenous solution, subcutaneous kit, subcutaneous solution

Immunologic

Very common (10% or more): Immunogenicity (24%), infections (e.g., cellulitis, osteomyelitis, sepsis, herpes zoster) (22%)

Common (1% to 10%): Tinea infections (e.g., tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection)[Ref]

Local

Common (1% to 10%): Injection site reactions (e.g., bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth)[Ref]

Respiratory

Very common (10% or more): Upper respiratory infections (e.g., respiratory tract infection [viral, bacterial, unspecified], sinusitis [including acute], rhinitis, nasopharyngitis, pharyngitis [including viral], tonsillitis) (13%)[Ref]

Other

Common (1% to 10%): Fatigue, asthenia[Ref]

Nervous system

Common (1% to 10%): Headache (e.g., tension headache, sinus headache, cervicogenic headache)[Ref]

Dermatologic

Uncommon (0.1% to 1%): Folliculitis, urticaria[Ref]

Frequently asked questions

References

1. "Product Information. Skyrizi (risankizumab)." AbbVie US LLC (2019):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.